- Home
- HURA vs PYPD Comparison
HURA vs PYPD Comparison
Compare HURA & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | PYPD |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | Israel |
| Employees | 19 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 77.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HURA | PYPD |
|---|---|---|
| Price | $2.12 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 899.6K | 44.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $2.30 |
| 52 Week High | $4.41 | $5.12 |
Technical Indicators
Market Signals| Indicator | HURA | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 58.45 |
| Support Level | $1.56 | $4.26 |
| Resistance Level | $2.16 | $5.05 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 85.25 | 77.04 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.